Literature DB >> 24319508

Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

Jo-An Seah1, Normand Blais, Scott North, Yasmin Rahim, Dean Ruether, Peter C Black, Alexandre R Zlotta, Lori Wood, Srikala S Sridhar.   

Abstract

Neoadjuvant chemotherapy (NC) improves overall survival in patients with resectable muscle-invasive urothelial cancer of the bladder (MIBC). However uptake of NC in Canada is dis-appointingly low. Following a detailed literature review and in consultation with urologic oncology, the Canadian Association of Genitourinary Medical Oncologists (CAGMO) has developed a consensus statement for the use of NC in MIBC. Our primary goal is to increase the uptake of NC for MIBC in Canada and improve patient outcomes.

Entities:  

Year:  2013        PMID： 24319508      PMCID： PMC3854467          DOI： 10.5489/cuaj.1506

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  30 in total

Review 1.  Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens.

Authors:  D Raghavan; B Pearson; W H Watt; H Mameghan; P Langdon; D Eisinger; R Wines
Journal:  Semin Oncol       Date:  1991-02       Impact factor: 4.929

Review 2.  Prevention and management of complications following radical cystectomy for bladder cancer.

Authors:  Nathan Lawrentschuk; Renzo Colombo; Oliver W Hakenberg; Seth P Lerner; Wiking Månsson; Arthur Sagalowsky; Manfred P Wirth
Journal:  Eur Urol       Date:  2010-02-26       Impact factor: 20.096

3.  Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2.

Authors:  Amir Sherif; Erkki Rintala; Oddvar Mestad; Jonas Nilsson; Lars Holmberg; Sten Nilsson; Per-Uno Malmström
Journal:  Scand J Urol Nephrol       Date:  2002

4.  Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort.

Authors:  P Bassi; G D Ferrante; N Piazza; R Spinadin; R Carando; G Pappagallo; F Pagano
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

Review 5.  Update on chemotherapy for advanced bladder cancer.

Authors:  Jonathan E Rosenberg; Peter R Carroll; Eric J Small
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

6.  Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.

Authors:  Robert S Svatek; Mark B Fisher; Surena F Matin; Ashish M Kamat; H Barton Grossman; Graciela M Nogueras-González; Diana L Urbauer; Kathleen A Kennedy; Colin P Dinney
Journal:  J Urol       Date:  2010-01-18       Impact factor: 7.450

Review 7.  Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.

Authors:  Bertram E Yuh; Nora Ruel; Timothy G Wilson; Nicholas Vogelzang; Sumanta K Pal
Journal:  J Urol       Date:  2012-11-01       Impact factor: 7.450

8.  Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

Authors:  S Machele Donat; Ahmad Shabsigh; Caroline Savage; Angel M Cronin; Bernard H Bochner; Guido Dalbagni; Harry W Herr; Matthew I Milowsky
Journal:  Eur Urol       Date:  2008-07-14       Impact factor: 20.096

9.  Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group.

Authors:  P U Malmström; E Rintala; R Wahlqvist; P Hellström; S Hellsten; E Hannisdal
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

Review 10.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321
View more
  13 in total

1.  Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time.

Authors:  Geoffrey T Gotto; Melissa A Shea-Budgell; M Sarah Rose; J Dean Ruether
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  [Not Available].

Authors:  Christopher M Booth; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

3.  Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario.

Authors:  Christopher M Booth; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

4.  Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Authors:  Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2019-01-31       Impact factor: 1.862

5.  Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49th parallel.

Authors:  Michael J Raphael; Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2019-02       Impact factor: 1.862

6.  Optimizing care and outcomes of patients with muscle-invasive bladder cancer.

Authors:  Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

7.  Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice.

Authors:  Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

8.  Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.

Authors:  Tina Hsu; Peter C Black; Kim N Chi; Christina M Canil; Bernhard J Eigl; Girish Kulkarni; Scott North; Lori Wood; Alexandre R Zlotta; Anthea Lau; Tony Panzarella; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

9.  Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Authors:  Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

10.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.